NeuroSearch receives payment from BI for drug development  

2005.01.26
Danish biopharmaceutical company NeuroSearch has received DKK 28.6 mn (USD 5mn) from Boehringer Ingelheim for the continuation of the development of NS2330

Danish biopharmaceutical company NeuroSearch has received DKK 28.6 mn (USD 5 mn) from Boehringer Ingelheim for the continuation of the development of the drug candidate NS2330 for the treatment of Alzheimer's and Parkinson's disease. The payment is in accordance with the development and licensing agreement between the two companies.

 

NS2330 is currently in clinical Phase II studies where it is being tested in 930 patients. The results are expected to be available mid-summer, and Boehringer Ingelheim will subsequently decide on the initiation of Phase III studies.

 

NeuroSearch focuses on developing new and innovative drugs for the treatment of CNS diseases. It has five compounds in clinical development and a portfolio of drug discovery programmes. NeuroSearch is listed on Copenhagen Stock Exchange. The news is reported by national daily newspaper Jyllands-Posten and on NeuroSearch's website.

 

Link > NeuroSearch 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×